Genmab Performance degli utili passati
Criteri Il passato verificati 2/6
Genmab ha registrato una crescita degli utili a un tasso medio annuo di 18%, mentre il settore Biotechs ha registrato utili in crescita a un tasso medio annuo di 17%. I ricavi sono stati in crescita a un tasso medio annuo di 23.6%. Il ritorno sul capitale proprio di Genmab è 14.4% e ha margini netti di 21%.
Informazioni chiave
18.05%
Tasso di crescita degli utili
19.10%
Tasso di crescita dell'EPS
| Biotechs Crescita del settore | 18.72% |
| Tasso di crescita dei ricavi | 23.62% |
| Rendimento del capitale proprio | 14.45% |
| Margine netto | 21.05% |
| Prossimo aggiornamento sugli utili | 06 Aug 2026 |
Aggiornamenti sulle prestazioni recenti
Recent updates
Articolo di analisi • May 15
There May Be Some Bright Spots In Genmab's (CPH:GMAB) Earnings
The most recent earnings report from Genmab A/S ( CPH:GMAB ) was disappointing for shareholders. While the headline...Articolo di analisi • May 11
Analyst Estimates: Here's What Brokers Think Of Genmab A/S (CPH:GMAB) After Its First-Quarter Report
Genmab A/S ( CPH:GMAB ) shareholders are probably feeling a little disappointed, since its shares fell 3.9% to kr.1,642...
Aggiornamento della narrazione • Apr 29
GMAB: 2026 Pipeline Catalysts Will Test Balanced Risk And Opportunity Outlook
Narrative Update on Genmab The updated analyst framework lifts Genmab's fair value estimate from DKK 1,300 to about DKK 1,588. This reflects higher assumed revenue growth and P/E multiples as analysts factor in recent upgrades, resumed coverage and new acquisition driven pipeline contributions.
Aggiornamento della narrazione • Apr 15
GMAB: 2026 Clinical Readouts And AI Use Will Shape Outlook
Genmab's updated analyst price target edges slightly lower to DKK 2,233 from DKK 2,238, as analysts factor in mixed views around Epkinly assumptions, acquisition driven pipeline updates, and a modestly higher future P/E expectation despite broadly constructive long term growth potential. Analyst Commentary Recent research on Genmab reflects a mix of optimism around the expanded pipeline and upcoming catalysts, alongside caution tied to Epkinly assumptions and valuation.
Aggiornamento della narrazione • Mar 31
GMAB: 2026 Late Stage Oncology Catalysts Will Support Stronger Margin Profile
Genmab's updated analyst price target now sits at DKK 3,017, a modest reset from DKK 3,060 as analysts factor in higher discount rates, revised long term margin expectations, and recent research that reflects both increased revenue growth assumptions and a lower future P/E multiple. Analyst Commentary Recent Street research around Genmab has centered on how new clinical and portfolio developments filter into valuation, with several bullish analysts updating price targets and investment cases to reflect revised expectations on execution and long term growth potential.Aggiornamento della narrazione • Mar 17
GMAB: 2026 Catalyst Calendar Will Likely Expose Downside Risk Ahead
Analysts have lifted the Genmab fair value estimate from DKK 1,075.93 to DKK 1,300.00, reflecting updated views on revenue growth, profitability and future P/E, following recent price target revisions and renewed coverage across the Street. Analyst Commentary Recent Street research on Genmab points to a mix of optimism and caution, with valuation views reset around updated expectations for key pipeline assets and royalty streams.Aggiornamento della narrazione • Mar 03
GMAB: 2026 Catalyst Events And AI Adoption Will Shape Outlook
Genmab's analyst fair value estimate has moved up from DKK 2,182 to DKK 2,238, as analysts factor in higher long term revenue growth assumptions, a higher future P/E and recent price target revisions around DKK 2,400 to DKK 2,500, even as they temper near term expectations for Epkinly and margins. Analyst Commentary Recent research points to a more nuanced view of Genmab, with several firms adjusting their price targets and models following the latest earnings, product updates and acquisition activity.Aggiornamento della narrazione • Feb 17
GMAB: 2026 Pipeline Readouts And AI Use Will Drive Outlook
Analysts have made a small trim to their blended DKK price target on Genmab, with the model now pointing to roughly DKK 2,182. This reflects updated assumptions around slightly higher discount rates, a modestly different margin outlook and a lower future P/E multiple after recent coverage resets and target hikes from banks like Morgan Stanley, Deutsche Bank and Barclays.Aggiornamento della narrazione • Feb 02
GMAB: Phase 3 Data, AI Adoption And 2026 Readout Will Shape Outlook
Genmab’s analyst fair value estimate has moved modestly higher to DKK 2,188.94. Analysts point to updated assumptions around slightly lower discount rates, adjusted revenue growth and profit margin expectations, and a recalibrated future P/E multiple as the key drivers behind the refreshed price targets.Aggiornamento della narrazione • Jan 19
GMAB: Phase 3 Setback And 2026 Readout Will Shape Market Outlook
Genmab’s analyst price target has been lifted by roughly DKK 100 to reflect updated expectations around slightly higher revenue growth and profit margin assumptions, as analysts point to recent target increases from DKK 2,000 to DKK 2,400 and DKK 2,500 as support for a higher fair value range. Analyst Commentary Recent Street research on Genmab reflects a generally constructive stance, with higher price targets and continued attention on upcoming clinical milestones.Aggiornamento della narrazione • Jan 05
GMAB: Late Stage Oncology Focus Will Drive Stronger Margins And Repricing
Analysts have increased their fair value estimate for Genmab from DKK 2,700 to approximately DKK 3,060, reflecting updated assumptions that combine lower projected revenue growth with higher profit margins and a reduced future P/E multiple. What's in the News Genmab plans to discontinue further clinical development of acasunlimab and to concentrate resources on late stage programs such as EPKINLY (epcoritamab), petosemtamab and rinatabart sesutecan, described as part of its disciplined portfolio and capital allocation framework (Key Developments).Aggiornamento della narrazione • Dec 14
GMAB Merus Deal Will Likely Expose Downside Risk At Current Levels
Analysts have lifted Genmab's fair value estimate from DKK 1,015 to about DKK 1,076, reflecting a series of higher price targets that cite the Merus acquisition's boost to the late stage pipeline and underappreciated royalty revenue upside as key drivers. Analyst Commentary Recent Street research on Genmab remains broadly constructive, with multiple firms lifting price targets and highlighting the strategic merits of the Merus acquisition.Aggiornamento della narrazione • Nov 29
GMAB: Merus Acquisition and Pipeline Depth Will Shape Market Outlook
Genmab's analyst price target has seen a modest decrease of approximately DKK 3.57 to DKK 2,054.66. Analysts are factoring in sustaining growth drivers from recent pipeline acquisitions while adjusting for updates to discount rate and margin assumptions.Aggiornamento della narrazione • Nov 15
GMAB: Future Pipeline Expansion and Merus Acquisition Will Define Performance
Genmab's analyst price target has been raised from approximately DKK 2,017 to DKK 2,058. This reflects analysts' increased confidence in the company's pipeline expansion, notably following the Merus acquisition and upside potential from key assets such as Epkinly.Aggiornamento della narrazione • Nov 01
GMAB: Recent Acquisition Will Drive Pipeline Expansion While Integration Risks Remain
Genmab's fair value estimate has been raised from DKK 2,012.92 to DKK 2,017.35. Analysts highlight the Merus acquisition's positive impact on the late-stage pipeline and renewed confidence in royalty revenue growth opportunities.Aggiornamento della narrazione • Oct 18
Pipeline Progress And International Expansion Will Unlock Market Opportunities
Genmab's analyst fair value target has increased slightly, rising from DKK 2,005 to DKK 2,013. Analysts cite royalty revenue upside and pipeline expansion following recent M&A activity as key drivers for the upward revisions.Aggiornamento della narrazione • Oct 04
Pipeline Progress And International Expansion Will Unlock Market Opportunities
Genmab's analyst price target was raised from approximately $1,942 to $2,005. This reflects increased confidence among analysts in the company's growth outlook and pipeline expansion following recent acquisitions.Articolo di analisi • Sep 24
Here's Why We Think Genmab (CPH:GMAB) Might Deserve Your Attention Today
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Aggiornamento della narrazione • Sep 04
Pipeline Progress And International Expansion Will Unlock Market Opportunities
Genmab’s consensus price target was unchanged at DKK1942, as strong sales momentum and positive pipeline updates were offset by concerns about rising competition and tempered long-term growth expectations. Analyst Commentary Bullish analysts are raising price targets following stronger-than-expected sales momentum for Genmab's key oncology products.Articolo di analisi • Jul 31
Investors Aren't Entirely Convinced By Genmab A/S' (CPH:GMAB) Earnings
When close to half the companies in Denmark have price-to-earnings ratios (or "P/E's") above 16x, you may consider...
Nuova narrazione • Nov 11
Decisive Advances And DuoBody Innovation Propel Future Growth In Biotech Frontiers
Genmab's focus on late-stage therapies, particularly EPKINLY, is expected to boost future revenue and growth due to best-in-class technology and market approvals.Ripartizione dei ricavi e delle spese
Ripartizione dei ricavi e delle spese
Come Genmab guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.
Storico di utili e ricavi
| Data | Ricavi | Utili | Spese G+A | Spese di R&S |
|---|---|---|---|---|
| 31 Mar 26 | 3,901 | 821 | 666 | 1,687 |
| 31 Dec 25 | 3,720 | 963 | 626 | 1,606 |
| 30 Sep 25 | 3,846 | 1,583 | 643 | 1,567 |
| 30 Jun 25 | 3,647 | 1,371 | 624 | 1,550 |
| 31 Mar 25 | 3,233 | 1,136 | 550 | 1,438 |
| 31 Dec 24 | 3,121 | 1,133 | 549 | 1,414 |
| 30 Sep 24 | 2,964 | 702 | 519 | 1,349 |
| 30 Jun 24 | 2,743 | 798 | 501 | 1,276 |
| 31 Mar 24 | 2,576 | 791 | 504 | 1,187 |
| 01 Jan 24 | 2,390 | 631 | 478 | 1,107 |
| 30 Sep 23 | 2,389 | 590 | 466 | 1,033 |
| 30 Jun 23 | 2,378 | 680 | 453 | 979 |
| 31 Mar 23 | 2,216 | 757 | 422 | 890 |
| 31 Dec 22 | 2,088 | 785 | 385 | 801 |
| 30 Sep 22 | 1,580 | 745 | 299 | 688 |
| 30 Jun 22 | 1,438 | 558 | 268 | 683 |
| 31 Mar 22 | 1,342 | 354 | 228 | 667 |
| 31 Dec 21 | 1,288 | 452 | 196 | 640 |
| 30 Sep 21 | 1,232 | 448 | 156 | 590 |
| 30 Jun 21 | 1,168 | 401 | 134 | 541 |
| 31 Mar 21 | 1,703 | 880 | 119 | 512 |
| 31 Dec 20 | 1,660 | 781 | 108 | 515 |
| 30 Sep 20 | 1,736 | 889 | 86 | 453 |
| 30 Jun 20 | 1,559 | 853 | 73 | 417 |
| 31 Mar 20 | 837 | 349 | 56 | 378 |
| 31 Dec 19 | 806 | 325 | 51 | 358 |
| 30 Sep 19 | 532 | 223 | 42 | 317 |
| 30 Jun 19 | 487 | 178 | 39 | 291 |
| 31 Mar 19 | 441 | 202 | 36 | 250 |
| 31 Dec 18 | 464 | 226 | 33 | 220 |
| 30 Sep 18 | 437 | 222 | 30 | 191 |
| 30 Jun 18 | 397 | 194 | 28 | 174 |
| 31 Mar 18 | 462 | 213 | 26 | 164 |
| 31 Dec 17 | 381 | 178 | 24 | 137 |
| 30 Sep 17 | 361 | 184 | 21 | 126 |
| 30 Jun 17 | 356 | 208 | 19 | 110 |
| 31 Mar 17 | 272 | 174 | 16 | 101 |
| 31 Dec 16 | 257 | 168 | 14 | 94 |
| 30 Sep 16 | 221 | 111 | 15 | 97 |
| 30 Jun 16 | 205 | 102 | 14 | 90 |
| 31 Mar 16 | 183 | 82 | 14 | 81 |
| 31 Dec 15 | 165 | 111 | 13 | 71 |
| 30 Sep 15 | 116 | 66 | 14 | 66 |
| 30 Jun 15 | 115 | 69 | 14 | 66 |
Guadagni di qualità: GMAB ha guadagni di alta qualità.
Margine di profitto in crescita: Gli attuali margini di profitto netti di GMAB (21%) sono inferiori rispetto allo scorso anno (35.1%).
Flusso di cassa libero e analisi degli utili
Analisi della crescita degli utili nel passato
Andamento degli utili: Gli utili di GMAB sono cresciuti del 18% all'anno negli ultimi 5 anni.
Accelerare la crescita: GMAB ha avuto una crescita negativa degli utili nell'ultimo anno, quindi non può essere confrontata con la sua media quinquennale.
Guadagni vs Settore: GMAB ha avuto una crescita negativa degli utili ( -27.7% ) nell'ultimo anno, rendendo difficile il confronto con la media del settore Biotechs ( 45% ).
Rendimento del capitale proprio
ROE elevato: Il Return on Equity ( 14.4% ) di GMAB è considerato basso.
Rendimento delle attività
Rendimento del capitale investito
Scoprire le aziende con forti performance passate
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/05/22 04:55 |
| Prezzo dell'azione a fine giornata | 2026/05/22 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Genmab A/S è coperta da 41 analisti. 22 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| James Gordon | Barclays |
| Xue Chen | Barclays |
| Emily Field | Barclays |